Coherus BioSciences (Nasdaq:CHRS) - Cotización, noticias y análisis

Resumen de acción CHRS

Coherus BioSciences, Inc. es una empresa biofarmacéutica dedicada a la investigación, desarrollo y comercialización de tratamientos contra el cáncer, principalmente en Estados Unidos.

Acerca de la empresa

CHRS fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	4/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los beneficios de 79.71%

Cotiza a buen valor en comparación con empresas similares e industria

Análisis de riesgos

Tiene menos de 1 año de cash runway

Patrimonio neto negativo

Los accionistas han sido diluidos en el último año

Volatilidad del precio de la acción en los últimos 3 meses

Competidores de Coherus BioSciences, Inc.

uniQure

NasdaqGS:QURE

US$221.7m

Adverum Biotechnologies

NasdaqCM:ADVM

US$203.2m

Amarin

NasdaqGM:AMRN

US$344.7m

Agenus

NasdaqCM:AGEN

US$278.4m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Coherus BioSciences
Historical stock prices
Current Share Price	US$2.17
52 Week High	US$8.22
52 Week Low	US$1.43
Beta	0.51
1 Month Change	-8.05%
3 Month Change	5.34%
1 Year Change	-70.36%
3 Year Change	-85.03%
5 Year Change	-86.52%
Change since IPO	-82.79%

Noticias y actualizaciones recientes

Coherus Biosciences: Dumping One Drug But Showing Promise With Another

Mar 21

Recent updates

Coherus Biosciences: Dumping One Drug But Showing Promise With Another

Mar 21

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive

Feb 03

Coherus BioSciences: FDA Approvals Spice Up The Pipeline

Jan 17

Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues

Dec 20

The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically

May 13

Coherus to launch its biosimilar to Roche's eye disorder drug Lucentis in U.S. on Oct. 3

Sep 19

Coherus: 2022 Is In Many Ways A Make Or Break Year

Aug 24

Coherus stock soars 14% on FDA nod for Roche Lucentis' interchangeable biosimilar Cimerli

Aug 03

Coherus, Shanghai Junshi refiling for toripalimab gets FDA review in rare head/neck cancer

Jul 06

Would Coherus BioSciences (NASDAQ:CHRS) Be Better Off With Less Debt?

Jun 15

Coherus: Will Its Chinese Gambit Fail?

May 27

Rentabilidad de los accionistas

	CHRS	US Biotechs	Mercado US
7D	12.4%	2.7%	0.3%
1Y	-70.4%	2.9%	24.2%

Rentabilidad vs. Industria: CHRS obtuvo unos resultados inferiores a los del sector US Biotechs , que el año pasado arrojó un rendimiento del -2.3%.

Rentabilidad vs. Mercado: CHRS obtuvo unos resultados inferiores a los del mercado US, que fue del 19.3% el año pasado.

Volatilidad de los precios

Is CHRS's price volatile compared to industry and market?
CHRS volatility
CHRS Average Weekly Movement	11.3%
Biotechs Industry Average Movement	11.6%
Market Average Movement	6.1%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: El precio de las acciones de CHRS ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de CHRS(11%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2010	306	Denny Lanfear	www.coherus.com

Coherus BioSciences, Inc. es una empresa biofarmacéutica dedicada a la investigación, el desarrollo y la comercialización de tratamientos contra el cáncer, principalmente en Estados Unidos. La empresa desarrolla UDENYCA, un biosimilar de Neulasta, un factor estimulante de colonias de granulocitos de acción prolongada; LOQTORZI, un nuevo inhibidor de PD-1; y Casdozokitug, un anticuerpo monoclonal recombinante de inmunoglobulina humana de isotipo G1 (IgG1) dirigido a la interleucina 27. También está desarrollando CHS-114, un anticuerpo monoclonal de alta actividad contra el cáncer.

Resumen de fundamentos de Coherus BioSciences, Inc.

¿Cómo se comparan los beneficios e ingresos de Coherus BioSciences con su capitalización de mercado?
Estadísticas fundamentales de CHRS
Capitalización bursátil	US$233.81m
Beneficios(TTM)	-US$237.89m
Ingresos (TTM)	US$257.24m

1.0x

Ratio precio-ventas (PS)

-1.0x

Ratio precio-beneficio (PE)

¿Está CHRS sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de CHRS
Ingresos	US$257.24m
Coste de los ingresos	US$158.99m
Beneficio bruto	US$98.25m
Otros gastos	US$336.14m
Beneficios	-US$237.89m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

May 09, 2024

Beneficios por acción (BPA)	-2.10
Margen bruto	38.19%
Margen de beneficio neto	-92.48%
Ratio deuda/patrimonio	-244.7%

¿Cómo se ha desempeñado CHRS a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción CHRS

Recompensas

Análisis de riesgos

Competidores de Coherus BioSciences, Inc.

NasdaqGS:QURE

US$221.7m

NasdaqCM:ADVM

US$203.2m

NasdaqGM:AMRN

US$344.7m

NasdaqCM:AGEN

US$278.4m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Coherus BioSciences, Inc. to Report Q1, 2024 Results on May 09, 2024

Coherus BioSciences, Inc. Announces Presentation of Clinical Data for CHS-114 at 2024 American Society of Clinical Oncology Annual Meeting

Coherus BioSciences, Inc., Annual General Meeting, May 29, 2024

Consensus EPS estimates upgraded to US$0.55 loss, revenue downgraded

Coherus Biosciences: Dumping One Drug But Showing Promise With Another

Forecast breakeven date pushed back to 2026

Recent updates

Coherus BioSciences, Inc. to Report Q1, 2024 Results on May 09, 2024

Coherus BioSciences, Inc. Announces Presentation of Clinical Data for CHS-114 at 2024 American Society of Clinical Oncology Annual Meeting

Coherus BioSciences, Inc., Annual General Meeting, May 29, 2024

Consensus EPS estimates upgraded to US$0.55 loss, revenue downgraded

Coherus Biosciences: Dumping One Drug But Showing Promise With Another

Forecast breakeven date pushed back to 2026

Coherus BioSciences, Inc. to Report Q4, 2023 Results on Mar 13, 2024

New major risk - Financial position

Coherus BioSciences, Inc. Announces U.S. Launch of UDENYCA ONBODY a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Lead Independent Director exercised options to buy US$139k worth of stock.

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive

Sandoz Group AG (SWX:SDZ) entered into a definitive agreement to acquire CIMERLI an ophthalmology franchise from Coherus BioSciences, Inc. (NasdaqGM:CHRS) for approximately $170 million.

Sandoz Group AG (SWX:SDZ) entered into a definitive agreement to acquire CIMERLI an ophthalmology franchise from Coherus BioSciences, Inc. (NasdaqGM:CHRS) for approximately $170 million.

Coherus BioSciences, Inc. Presents Positive Phase 2 Clinical Data on Casdozokitug, A First-In-Class IL-27-Targeted Antibody, At the 2024 ASCO GI Cancers Symposium

Coherus BioSciences: FDA Approvals Spice Up The Pipeline

Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues

Coherus BioSciences, Inc. Appoints Bryan McMichael as Principal Financial Officer

Coherus BioSciences, Inc. Announces Resignation of McDavid Stilwell as Chief Financial Officer, Effective December 31, 2023

Coherus BioSciences, Inc. Presents Phase 1/2 Clinical Data on Casdozokitug at the 2023 ESMO Immuno-Oncology Congress

Coherus and Junshi Biosciences Announces Publication of Positive Final Overall Survival Results of Jupiter-02, A Phase 3 Trial Evaluating Loqtorzi (Toripalimab-Tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association

Chairman notifies of intention to sell stock

Consensus revenue estimates fall by 12%

New major risk - Share price stability

Coherus Biosciences, Inc. Lowers Its Revenue Guidance for 2023

Coherus Biosciences, Inc. Lowers Its Revenue Guidance for 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target increased by 7.3% to US$12.88

Coherus BioSciences, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Coherus Biosciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Biosciences Announce FDA Approval of Loqtorzi (Toripalimab-Tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

Coherus BioSciences, Inc. Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Price target decreased by 7.6% to US$12.11

Coherus Biosciences, Inc. Announces Resubmission of Biologics License Application (Bla) Supplement for Udenyca(R) Onbody

FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus BioSciences, Inc Also Announces Completion of Toripalimab FDA Inspections

Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others.

New major risk - Share price stability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Coherus Biosciences, Inc. Provides Revenue Guidance for the Year 2023

Coherus BioSciences, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Coherus Biosciences, Inc. Announces Appointment of Michael Ryan to Board of Directors

Coherus Launches Yusimry™, A Biosimilar of Humira®

Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million.

Price target decreased by 12% to US$13.63

Coherus BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million.

Price target decreased by 13% to US$15.56

Coherus BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million.

Consensus revenue estimates fall by 13%

The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically

Coherus BioSciences, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$1.09 loss

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Shanghai Junshi Biosciences Co., Ltd and Coherus Biosciences, Inc. Announce Positive Results of A Final Analysis of Overall Survival from the Pivotal Study JUPITER-02

Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Coherus BioSciences, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology

Coherus to Launch Cimerli (Ranibizumab-Eqrn) in the United States on October 3, 2022